Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels

Thyroid

Volumn 6, Issue 4, 1996, Pages 283-288

  Ozata, Metin ^a,b   Bolu, Erol ^a   Sengul, Ali ^a   Tasar, Mustafa ^a   Beyhan, Zeynel ^a   Corakci, Ahmet ^a   Gundogan, M Ali ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; INTERCELLULAR ADHESION MOLECULE 1; OCTREOTIDE; PROPRANOLOL; THIAMAZOLE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOPHTHALMOS; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; GRAVES DISEASE; HUMAN; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0029745335     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.1996.6.283     Document Type: Article

References (42)

1. Wiersinga WM 1992 Immunosuppressive treatment of Graves' ophthalmopathy. Thyroid 2:229-233.
2. Perros P, Weightman DR, Crombie AC, Kendall Taylor P 1990 Azothioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol 122:8-12.
3. Bigos STh, Nisula BC, Daniels GH, Eastman RC, Johnson HH, Kohler PO 1979 Cyclophosphamide in the management of advanced Graves' ophthalmopathy. A preliminary report. Ann Intern Med 90:921-923.
4. Prummel MF, Mourits MPh, Berghout A, Krenning EP, Van der Gaag R, Koorneef L, Wiersinga WM 1989 Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 321:1353-1359.
5. Kahaly G, Lieb W, Muller-Forell W, Mainberger M, Beyer J, Vollmar J, Staiger C 1990 Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study. Acta Endocrinol 122:13-21.
6. Dandona P, Marshall NJ, Bidey SP, Nathan A, Havard CWH 1979 Successful treatment of exophthalmos and pretibial myxodema with plasmapheresis. Br Med J 1:374-376.
7. Antonelli A, Saracino A, Alberti B, Canapicchi R, Cartel F, Lepri A, Laddaga M, Baschieri L 1992 High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. Acta Endocrinol 126:13-23.
8. Sautter-Bihl ML, Heinze HG 1989 Radiotherapy of Graves'ophthalmopathey In: Pickardt CR, Boergen KP (eds) Graves' Ophthalmopathy. Developments in Diagnostic, Methods and Therapeutical Procedures. Dev Ophthalmol. Basel, Karger, vol. 20, pp 139-154.
9. Streeten DHP, Anderson GHJr, Reid GF, Wov P 1987 Prevalence, natural history and surgical treatment of exophtalmos. Clin Endocrinol 27:125-133.
10. Burch HB, Wartofsky L 1993 Graves' ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev 14:747-793.
11. DeGroot LJ, Gorman CA, Pinchera A, Bartelana L, Marocci C, Wiersinga WM, Prummel MF, Wartofsky L 1995 Therapeutic controversies. Radiation and Graves' ophthalmopathy. J Clin Endocrinol Metab 80:339-349.
12. Chang TC, Kao SCS, Huang KM 1992 Octreotide and Graves' ophthalmopathy and pretibial myxoedema. Br Med J 304:158.
13. Krassas GE, Dumas A, Pontikides N, Kaltsas T 1995 Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol 42:571-580.
14. Durak I, Durak H, Ergin M, Yürekli Y, Kaynak S 1995 Somatostatin receptors in the orbits. Clin Nucl Med 20:237-242.
15. Heufelder AE, Bahn RS 1993 Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases. Clin Exp Immunol 92:296-302.
16. De Bellis A, Bizzarro A, Gattoni A, Romano C, Di Martino S, Sinisi AA, Abbadessa S, Bellastella A 1995 Behaviour of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma. J Clin Endocrinol Metab 80:2118-2121.
17. Bahn RS 1995 Assessment and management of the patient with Graves' ophthalmopathy. Endocr Pract 1:172-178.
18. Mourits M Ph, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, Gaag RVD 1989 Clinical criteria for the assessment of disease activity: A novel approach. Br J Ophthalmol 73:639-644.
19. Hallin ES, Feldon SE 1988 Graves' ophthalmopathy: 1 Simple CT estimates of extraocular muscle volume. Br J Ophthalmol 72:674-677.
20. Peyster RG, Ginsberg F, Silber JH, Adler LP 1986 Exopthalmos caused by excessive fat:CT volumetric analysis and differential diagnosis. AJR 146:459-464.
21. Pabusşçu Y, Kizilkaya E, Tayfun C, Alemdaroǧlu H, Taşar M, Somuncu I1994 Computed tomographic diagnosis of exophthalmos. Bilgisayarli Tomografi Bülteni 3:77-81 (Turkish).
22. Wiersinga WM, Prummel MF, Mourits MPh, Koornneef L, Buller HR 1991 Classification of the eye changes of Graves' disease. Thyroid 1:357-360.
23. Tallstedt L, Lundell G, Torring O, Wallin G, Ljungren JG, Blomgren H, Taube A 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 326:1733-1738.
24. Wenisch C, Myskiw D, Gessl A, Graninger W 1995 Circulating selectins, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in hyperthyroidism. J Clin Endocrinol Metab 80:2122-2126.
25. Springer TA 1990 Adhesion receptors of the immune system. Nature (London) 346:425-434.
26. Needleman BN 1990 Increased expression of intercellular adhesion molecule 1 on the fibroblasts of scleroderma patients. Arthritis Rheum 33:1847-1851.
27. Sollberg S, Peltonen J, Uitto J, Jimenez SA 1990 Elevated expression of beta 1 and 2 integrins, intercellular adhesion molecule 1 and endothelial leucocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 35:290-298.
28. Furukawa S, Imai K, Matsubara T, Yone K, Yachi A, Okumura K, Yabuta K 1992 Increased levels of intercellular adhesion molecule in Kawasaki disease. Arthritis Rheum 35:672-677.
29. Wenisch C, Varijanonta S, Looareesuwan S, Graninger W, Pichler R, Wernsdorfer W 1994 Soluble intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and tumor necrosis factor receptor (55 kDa TNF-R) in patients with acute Plasmodium falciparum malaria. Clin Immunol Immunopathol 71:344-348.
30. Heulfelder AE, Bahn RS 1992 Modulation of intercellular adhesion molecule-1 (ICAM-1) by cytokines and Graves' IgGs in cultured Graves' retroocular fibroblasts. Eur J Clin Invest 22:529-537.
31. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA 1986 Induction by IL-1 and interferon-gamma:tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 137:245-254.
32. Wenisch C, Myskiw D, Parschalk B, Hartmann T, Dam K, Graninger W 1994 Soluble endothelium-associated adhesion molecules in patients with Graves' disease. Clin Exp Immunol 98:240-244.
33. 1] octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter for disease activity? J Clin Endocrinol Metab 79:1845-1851.
34. Shulkes A 1994 Somatostatin:physiology and clinical applications. Bailliere's Clin Endocrinol Metab 8:215-236.
35. Lamberts SWJ, Oosterom R, Neufeld M, Del Pozo E 1985 The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60:1161-1165.
36. Ghirlanda G, Uccioli L, Perri F, Altomonte L, Bertoli A, Manna R, Frati L, Greco AV 1983 Epidermal growth factor, somatostatin and psoriasis. Lancet 1:65.
37. Mascardo RN, Barton RN, Sherline P 1984 Somatostatin has an antiproliferative effect on concanavalin A activated rat thymocytes. Clin Immunol Immunopathol 33:131-138.
38. Viguerie N, Tahiri-Jouti N, Ayral AM, Cambillau C, Scemama JL, Bastie MJ, Knuhtsen S, Esteve JP, Pradayrol L, Susini C, Vaysse N 1989 Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism. Endocrinology 124:1017-1025.
39. Mascardo RN, Sherline P 1982 Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinology 111:1394-1396.
40. Schally AV 1988 Oncological applications of somatostatin analogues. Cancer Res 48:6977-6985.
41. Sridama V, DeGroot LJ 1989 Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 87:70-73.
42. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Pinchera A 1992 Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism. Thyroid 2:171-177.